Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV
Publication date
2024-08
Authors
Prunas, O.
Willemsen, J.
Warren, J. L.
Bont, Louis J
Schwartz, J. L.
Atwell, J.
Begier, E.
Dean, N.
Hirsch, I.
Karron, R.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
A meeting held in Lisbon, Portugal, in February 2023 focused on critical aspects of clinical trial design for respiratory syncytial virus (RSV) preventative therapies. The meeting addressed two primary areas: enhancing the efficiency and success of randomized controlled trials (RCTs) for RSV preventative therapies and designing RCTs to better inform post-licensure decision-making. Topics included the selection of primary endpoints, innovative approaches to incorporating multiple endpoints and historical data, and the challenges and benefits of sequential trial designs. The discussion also touched on meta-regression models for obtaining more robust, context-specific estimates of vaccine efficacy. Overall, the meeting underscored the importance of balancing efficiency and robustness in RSV vaccine trial design, while recognizing the need for further discussions involving regulatory and advisory bodies.
Keywords
Molecular Medicine, General Immunology and Microbiology, General Veterinary, Public Health, Environmental and Occupational Health, Infectious Diseases
Citation
Prunas, O, Willemsen, J, Warren, J L, Bont, L, Schwartz, J L, Atwell, J, Begier, E, Dean, N, Hirsch, I, Karron, R, Klugman, K, Kramer, R, Leidman, E, Link-Gelles, R, Nair, H, Panozzo, CA A, Pelfrene, E, Simões, E A F, Smith, P G, Srikantiah, P, Sundaram, M E, Thindwa, D, Vaughn, D W, Wilson, E, Zar, H J, Pitzer, V E & Weinberger, D M 2024, 'Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV', Vaccine: X, vol. 19, 100509. https://doi.org/10.1016/j.jvacx.2024.100509